As pharmaceutical companies face mounting pressure to accelerate innovation, expand pipelines, and identify external breakthroughs earlier, the intersection of traditional mergers & acquisitions with emerging decentralized technologies is becoming increasingly important.
Using qualitative case study methods, document analysis, and executive interviews within a global large-cap pharmaceutical company, the paper explores how innovation, partnerships, licensing, and acquisition strategies are evolving in response to digital transformation.
Key findings:
• AI, big data, and digital
platforms are improving innovation scouting, target identification, and forecasting
• Blockchain and DAOs may offer value in early-stage collaboration, decentralized innovation ecosystems, and academic/biotech visibility
• What slows adoption
Why this
matters:
This research highlights that decentralized technologies are not necessarily replacing conventional pharma strategy—but may become complementary tools that enhance how organizations discover, evaluate, and operationalize innovation.
Strategic implications for healthcare and life sciences leaders:
• Blending traditional acquisition + digital infrastructure
• Decentralized frameworks can reshape preclinical scouting and collaboration pathways
• Competitive advantages bridging institutional rigor with technological agility
For leaders in biopharma, corporate strategy, venture innovation, digital transformation, blockchain, and decentralized health ecosystems, this paper provides a valuable lens into where pharmaceutical innovation models may be headed next.
Read the full article DOI https://doi.org/10.30953/bhty.v9.435
Authors:
Simone Fantaccini, MD, MBA, PhD
Laura Grassi, PhD
Scott
Howell, MD, MBA
